Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>Events>This Event
  Events - April 2014

Biosimilars and Biobetters USA

07 Apr 2014 - 08 Apr 2014 - Iselin, NJ, USA

Bookmark and Share

Through a series of exciting panel discussions, presentations and workshops, delivered by true industry experts and players, this meeting will offer effective strategies and solutions for developing cost effective biosimilars for the future.

Read more:

After the phenomenal success of our Biosimilars and Biobetters event hosted in London in October, the SMi Group is delighted to announce the launch of the Biosimilars & Biobetters Conference in Iselin, New Jersey, USA, in April 2014. Registration is now open.

Through a series of exciting panel discussions, presentations and workshops, delivered by true industry experts and players, the Biosimilars and Biobetters USA conference will offer effective strategies and solutions for developing cost effective biosimilars for the future.

Event’s website: 

Benefits of attending:

-      Gain up to date insight into the regulatory landscape and how it is effecting the industry

-      Evaluate commercialization and development strategies to gain a competitive advantage 

-      Calculate possible revenue streams from biosimilar production

-      Discover what lessons have been learned so far and what the future holds 

-      Boost your industry knowledge and relationships by networking and learning from key industry and academic leaders

Key speakers include:

-      Dr Richard Dicicco, Chairman, Harvest Moon Pharmaceuticals

-      Dr John Pakulski, Senior Director, and Head US Biopharmaceutical Regulatory Affairs, Sandoz

-      Rodeina Challand, Executive Director, Biosimilars Development, Scientific Affairs, PRA International

-      Dr Stanley (SeungSuh) Hong, President, Research and Development, Celltrion Inc.

-      Paul Ashton, President & CEO, pSivida

-      Peter Pitts, President, Center for Medicine in the Public Interest (Former FDA Associate Commissioner)

-      Douglas M. Long, Vice President, Industry Relations, IMS Health

-      Dr Rakesh Dixit, Vice President, Research and Development Head, Global Biologics Safety Assessment, MedImmune (AstraZeneca Biologics), and many others. 

Don’t miss a chance to visit 2 interactive post-conference workshops:

A.    Differentiation Strategies for the Generics Industry. Workshop Leader: Asa Cox, Founder & CEO, Generic Pharma 2.0

B.    Launching a Biosimilar in an Innovator v. Generic World. Workshop Leader: Kristie Kuhl, JD, Executive VP, Makovsky

For further information please contact Jonathan Collins on +44 (0)20 7827 6734 or email:  

Further information
Scientific News
First Entirely 3D-printed Organ-on-a-Chip with Integrated Sensors
New approach to manufacturing may allow researchers to rapidly design organs-on-chips that match the properties of a specific disease or individual patient's cells.
Bacterial Genes Boost Current in Human Cells
Borrowing and tweaking bacterial genes to enhance electrical activity might treat heart, nervous system injury.
Targeting Cannabinoid CB2 Receptors in the CNS
With endogenous cannabinoids considered as a potential target to combat CNS diseases, this article examines the role of CB2R could play in fighting some disorders.
Less Frequent Cervical Cancer Screening
HPV-vaccinated women may only need one screening every 5 to 10 years with screening starting later in life.
Cocoa Compound Linked to Some Cardiovascular Biomarker Improvements
The study highlights the urgent need for large, long-term RCTs that improve understanding of how the short-term benefits of cocoa flavanol intake on cardiometabolic biomarkers may be translated into clinical outcomes.
Untangling a Cause of Memory Loss in Neurodegenerative Diseases
The mouse study identifies a possible therapeutic target for a family of disorders.
New Pathway for COPD Biomarker Development
A study from Philip Morris International has highlighted multi-lipid profiling as a potential new pathway for COPD biomarker development.
Stiffening a Blow to Cancer Cells
Researchers develop a way to predict how a tumor tissue's physical properties affect its response to chemotherapy drugs.
Anti-Cancer Drug Uses Tumour mRNA to Identify Responders
Phase I study of novel anti-cancer drug uses tumour mRNA expression to identify patients who will respond to the drug.
New Strategy for Choosing Cancer Drugs
Device can predict tumor responses by measuring cell growth after drug exposure.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos